2.30

7.48% 0.16

After Hours: 2.28 -0.02 -0.87%

Sangamo Therapeutics Inc (SGMO)

Overview News Price History Option Chain Financials Discussions Forecast

Sangamo Therapeutics Inc stock is traded at $2.30, with a volume of 5.08M. It is up +7.48% in the last 24 hours and up +53.33% over the past month. Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Previous Close:

$2.14

Open:

$2.14

24h Volume:

5.08M

Relative Volume:

0.71

Market Cap:

$448.59M

Revenue:

$176.23M

Net Income/Loss:

$-257.83M

P/E Ratio:

-1.5862

EPS:

-1.45

Net Cash Flow:

$-246.00M

1W Performance:

+17.95%

1M Performance:

+53.33%

6M Performance:

+286.42%

1Y Performance:

+515.80%

1-Day Range:

$2.09

$2.33

1-Week Range:

$1.79

$2.33

52-Week Range:

$0.304

$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name

Sangamo Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(510) 970-6000

Address

501 CANAL BLVD., RICHMOND, CA

Employee

405

Twitter

@sangamotx

Next Earnings Date

2024-10-30

Latest SEC Filings

SGMO's Discussions on Twitter

Compare SGMO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SGMO Sangamo Therapeutics Inc	2.30	448.59M	176.23M	-257.83M	-246.00M	-1.45
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral
Jun-13-22	Resumed	Wedbush	Neutral
May-04-21	Initiated	RBC Capital Mkts	Outperform
Jan-07-21	Resumed	Guggenheim	Neutral
Jan-06-21	Initiated	Stifel	Hold
Dec-16-20	Resumed	H.C. Wainwright	Buy
Sep-08-20	Initiated	BofA Securities	Buy
Jul-07-20	Initiated	SunTrust	Buy
Aug-26-19	Initiated	H.C. Wainwright	Buy
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-22-17	Resumed	Jefferies	Buy
Nov-01-16	Downgrade	Wedbush	Outperform → Neutral
Oct-19-16	Downgrade	Piper Jaffray	Overweight → Neutral
Dec-04-15	Initiated	Wells Fargo	Outperform
Oct-23-15	Resumed	Jefferies	Buy
May-03-13	Initiated	BioLogic Equity Research	Sell
Feb-23-11	Reiterated	JMP Securities	Mkt Outperform
Jul-29-10	Reiterated	Wedbush	Outperform
Oct-19-09	Initiated	Brean Murray	Sell
Oct-07-09	Reiterated	Leerink Swann	Outperform
Aug-25-09	Reiterated	JMP Securities	Mkt Outperform

View All

Sangamo Therapeutics Inc Stock (SGMO) Latest News

Nov 23, 2024

GSA Capital Partners LLP Sells 587,544 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Nov 23, 2024

Nov 22, 2024

Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 22, 2024

Nov 21, 2024

Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN

Nov 21, 2024

Nov 20, 2024

Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St

Nov 20, 2024

Nov 19, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace

Nov 19, 2024

Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com

Nov 19, 2024

Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan

Nov 19, 2024

Nov 18, 2024

What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat

Nov 18, 2024

Nov 15, 2024

FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat

Nov 15, 2024

Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat

Nov 14, 2024

Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada

Nov 14, 2024

Nov 13, 2024

Sangamo: Q3 Earnings Snapshot - Marketscreener.com

Nov 13, 2024

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia

Nov 13, 2024

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024

Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India

Nov 13, 2024